[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"transplant-dysfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:transplant-dysfunction":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,55,96],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":32,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100518030","expanding-the-scope-of-post-transplant-hla-specific-antibody-detection-and-monitoring-in-renal-transplant-recipients-100518030",false,"NCT06025240","Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients","HLA-AB","Inclusion Criteria:\n\n1. cf-DNA arm:\n\n   * Adult patients transplanted within 6-12 months (retrospective recruitment)\n   * Patients admitted for renal transplant or within the first 6 months following transplant (prospective recruitment)\n   * Patients must have capacity to provide informed consent\n   * Patients must have received a high-risk transplant defined as level 4 mismatch, cRF \\>20, second or subsequent transplant, ABO or HLA incompatible\n2. Older Age Immunological Events:\n\n   \\- Any adult patient with capacity undergoing, or within 72 hours of, a renal transplant\n3. Predictive models:\n\n   * Any adult patient with capacity undergoing, or within 72 hours of, a renal transplant\n   * Unsensitized pre-transplant\n\nExclusion Criteria:\n\n1. cf-DNA arm:\n\n   * Transplanted for longer than 12 months;\n   * Low risk transplants;\n   * Patients lacking capacity;\n2. Older Age Immunological Events:\n\n   * Patients lacking capacity\n   * Patients transplanted longer than 2 weeks\n3. Predictive models:\n\n   * Sensitised patients\n   * Patients lacking capacity\n   * Patients transplanted longer than 2 weeks","ALL","18 Years",{"count":19,"type":20},282,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to assess a new test to detect antibodies which may form following kidney transplant. These antibodies can be difficult to detect as they do not cause any symptoms but can lead to kidney damage. A new blood test will be performed alongside existing antibody tests to see how well the test functions in comparison and to see how well it is able to distinguish between inflammation caused by antibodies and other sorts of inflammation such as a urinary tract infection. The investigators also want to determine whether it is predictable whom will develop antibodies after a transplant and use these results to change the current way patients are monitored for antibodies after receiving a transplant. In addition to this, the investigators want to establish if patients over 60 years of age are relatively protected against immunological events such as rejection compared to patients who are under 60 years of age. The results could potentially lead to using a different immunosuppression regime based on which population age group patients belong to and lowering the risks associated with these drugs.",[24,25,26,27,28,29,30,31],"Kidney Transplant","Renal Transplant Failure","Kidney Transplant Rejection","Frailty","Kidney Transplant; Complications","Transplant Dysfunction","Diagnosis","Renal Transplant",[33,34,35,36,37,38,39,40,41],"kidney transplant","novel biomarkers","post-transplant antibodies","HLA-specific antibodies","donor specific antibodies","transplant in older age","machine learning","predictive models","rejection","RECRUITING","2024-08-28",{"date":45,"type":46},"2024-08-30","ACTUAL",{"date":48,"type":46},"2023-10-13",{"date":50,"type":20},"2026-10-13",{"name":52,"class":53},"Liverpool University Hospitals NHS Foundation Trust","OTHER_GOV",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":77,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":4},"100512344","liver-transplantation-after-ex-vivo-liver-perfusion-100512344","NCT05951231","Liver Transplantation After ex Vivo Liver Perfusion","Liver Transplantation After ex Vivo Liver Perfusion - The EVOLVE Study","EVOLVE","Inclusion Criteria:\n\n* Signed informed consent\n* ≥ 18 years\n* Indication for liver transplantation (one criteria must be met):\n* Colorectal cancer patients who have received 1st and 2nd line chemotherapy where the treatment has been stopped due to progression or toxicity and the patient is not eligible for SECA-2 (Survival Following Liver Transplantation for Patients With Nonresectable Liver-only Colorectal Metastases) study.\n* Hepatocellular carcinoma patients who are not suitable for standard liver transplantation, liver resection or local treatment (Transarterial Chemoembolisation or Selective internal radiotherapy). The patients must have progression or intolerance (toxicity) for immune checkpoint inhibitors or 1st line treatment.\n* Cholangiocarcinoma patients who have progression or intolerance to first-line chemotherapy.\n* Benign liver disease with urgent need for transplantation within months, but no regular graft is available.\n* Life expectancy ≤ 6 months\n* Willing, able and expected cooperation to attend follow-up examinations\n* Patients who have a need for liver transplantation but cannot participate in other transplant studies or participation in another clinical trial with randomization to liver transplantation.\n\nFor malignant disease the following criteria must be met:\n\n* Good performance status assessed at the discretion of the treating physician.\n* ECOG (Eastern Cooperative Oncology Group) 0 or 1\n* Satisfactory blood tests\n\n  * Hemoglobin \\>8 g\u002Fdl\n  * Neutrophiles \\>1.0 (after any Granulocyte colony-stimulating factor)\n  * Platelets \\>75\n  * Bilirubin \\\u003C1.5 x upper normal level\n  * ASAT (Aspartate aminotransferase), ALAT (alanine aminotransferase) \\\u003C5 x upper normal level\n  * Albumin above lower normal level.\n\nExclusion Criteria:\n\n* Already listed for ordinary Ltx with expectance of getting offered a regular liver graft within a reasonable time-frame.\n* Patients included in the control arm of the SECA-3 study or the Excalibur studies except for the Ltx arm of the Excalibur I study.\n* Mental conditions rendering the subject incapable to understand the nature, scope, and consequences of the trial.\n* Any reason why, in the opinion of the investigator, the patient should not participate.","100 Years",{"count":65,"type":20},22,"INTERVENTIONAL",[68],"NA","Today, it is difficult to predict liver function after transplantation and therefore livers where poor function is assumed (marginal livers) become discarded. The study aim is to increase the number of available donor livers, especially for liver cancer patients, by pre-treating and testing marginal ones (extended criteria donor (ECD) livers) liver on a liver perfusion machine. A liver perfusion machine can simulate liver transplantation and enables functional\u002Fquality testing before transplantation. The machine will hopefully also make marginal livers more functional by reducing ischemia- \\& reperfusion injury. A marginal donor liver is perfused ex situ with oxygenated blood from a blood donor on a machine. The liver can be tested here for function using internationally recognized criteria. At the same time, the investigators will carry out analyzes with microdialysis which can give a better picture of organ function and damage. Additionally, various samples of the liver and perfusate will be collected. Liver that achieves criteria for transplantation will be offered to the recipient.",[71,72,29,73,74,75,76],"Liver Transplant; Complications","Transplant; Failure, Liver","Transplant; Complication, Rejection","Transplant","Liver Metastases","Liver Cancer",[78,79,80,81,82,83,84],"Liver","Transplantation","Perfusion","Dual-end-ischemic Hypothermic Oxygenated Perfusion","Normothermic Machine Perfusion","Controlled Oxygenated Rewarming","Microdialysis","NOT_YET_RECRUITING","2023-10-31",{"date":88,"type":46},"2023-11-01",{"date":90,"type":20},"2024-02",{"date":92,"type":20},"2029-02",{"name":94,"class":95},"Oslo University Hospital","OTHER",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":66,"phases":105,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":54},"100351429","remote-ischaemic-preconditioning-in-transplantation-riptrans-100351429","NCT03855722","Remote Ischaemic Preconditioning in Transplantation (RIPTRANS)","Remote Ischaemic Preconditioning in Transplantation (RIPTRANS) - A Prospective Randomized Controlled Trial","Donor Inclusion Criteria:\n\n* Brain-dead organ donor with a plan of harvesting at least one kidney\n\nDonor Exclusion Criteria:\n\n* Haemodynamically unstable donor\n* Age below 18 years\n* Planned organ recipients are recruited to another prospective trial, which prevents participation in this trial.\n\nAll organ recipients receiving organs (kidney, liver, pancreas-kidney, heart, lungs) from a randomized donor will be recruited providing that the recipient surgery is performed at Helsinki University Hospital, recipient is over 18 years old, and recipient gives written informed consent to participate in the trial.",{"count":104,"type":20},496,[68],"Remote ischemic preconditioning (RIPC) is a concept where remotely induced ischemia produces protection against ischemia-reperfusion injury in a remote organ. RIPC has been studied extensively in animal models and heart surgery, but it's benefit in transplantation has been studied less. The primary aim of this study is to find out whether RIPC performed in a donor in donation after brain-death (DBD) could improve delayed graft function rate of kidney transplants.",[29],"2020-03-06",{"date":110,"type":46},"2020-03-10",{"date":112,"type":46},"2019-03-12",{"date":114,"type":20},"2042-02",{"name":116,"class":95},"Helsinki University Central Hospital"]